Initial Investment




NanoSyrinx is developing a unique synthetic biology platform, Nanosyringes, for targeted delivery of proteins and peptides directly into the interior of cells. This technology has many applications across in vivo and in vitro biology, including the potential to deliver therapies with improved efficiency, safety and economy. NanoSyrinx was co-founded in 2020 by Dr. Healey, Dr. Waterfield and Dr. Hapeshi to commercialise the team’s research at the University of Warwick’s Medical School. Dr Stephen Taylor, previously an SVP at Fujifilm Diosynth, has joined the company as Chairman, along with Dr. Jane Dancer, NED, whose past roles include CBO at F-Star and Director of Business Development at MedImmune. 

IQ Capital first invested in NanoSyrinx at Seed stage in 2021.